Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois 60637-1447

11 studies enrolling now · 39 studies all time

What they study most

AML, AML With Mutated NPM1, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, Acute T Cell Leukemia Lymphoma, Advanced Breast Cancer, Advanced Cancer

Studies at this site

• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• Busulfan Sample Collection Study — Recruiting now
• A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Recruiting now
• International Registry for Men With Advanced Prostate Cancer (IRONMAN) — Recruiting now
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
• The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias — Recruiting now
• Luspatercept + Darbepoetin in MDS — Recruiting now
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — Recruiting now
• Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen — Recruiting now
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) — Recruiting now
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — Recruiting now
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
• First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia — Running, not enrolling
• A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function — Stopped early
• A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors — Completed
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• 9-ING-41 in Patients With Advanced Cancers — Running, not enrolling
• Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas — Running, not enrolling
• Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Completed
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• A Study of AGEN2034 in Advanced Tumors and Cervical Cancer — Completed
• A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) — Completed
• A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma — Stopped early
• Telephone Support for Metastatic Breast Cancer Patients — Completed
• A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes — Stopped early
• A Study of FT-7051 in Men With MCRPC — Stopped early
• Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma — Status unconfirmed
• Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation — Completed
• Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) — Stopped early
• A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission — Stopped early
• A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors — Completed
• Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC — Stopped early
• Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma — Withdrawn before enrolling
• A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma — Completed
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed
• Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma — Completed
• Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer — Completed
• Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling — Withdrawn before enrolling